The European Medicines Agency's Human Medicines Committee (CHMP) on Friday issued a negative opinion for Omeros Corp.'s (NASDAQ:OMER) narsoplimab. • Omeros stock is feeling bearish pressure.
Why is OMER stock dropping?
The company was seeking approval for Yartemlea (narsoplimab) for adults and children from two years of age with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Thrombotic microangiopathy is a serious and potentially life-threatening complication following HSCT, a procedure in which the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells.
Read Also: Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication EMA Cites Study Design Concerns And Limited Pediatric Data The EMA panel said the company failed to provide sufficient evidence to demonstrate Yartemlea's effectiveness.
